Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

被引:120
作者
Tonolo, G
Melis, MG
Formato, M
Angius, MF
Carboni, A
Brizzi, P
Ciccarese, M
Cherchi, GM
Maioli, M
机构
[1] Univ Sassari, Ist Clin Med, Chair Metab Dis, I-07100 Sassari, Italy
[2] Univ Sassari, Dept Physiol Biochem & Cellular Sci, I-07100 Sassari, Italy
关键词
glycosaminoglycans; metabolic syndrome; microalbuminuria; NIDDM;
D O I
10.1046/j.1365-2362.2000.00735.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Experimental evidence indicates that statins might have direct vascular effects independently from low-density lipoprotein (LDL) cholesterol reduction and we reported that the reduction in urinary albumin excretion rate during Simvastatin treatment in type 2 diabetic patients was not correlated with LDL-cholesterol decrease. However in humans there are no data regarding possible additional effects of Simvastatin on blood pressure and urinary albumin excretion beyond its capacity to lower serum cholesterol. Patients and methods Twenty-six microalbuminuric hypertensive type 2 diabetic patients (diastolic blood pressure - after four months wash-out from the previous antihypertensive therapy - consistently > 90 and < 100 mmHg; plasma LDL-cholesterol > 3.9 and < 6.5 mmol L-1) were enrolled in the study. In random order, these patients received Simvastatin (20 mg day(-1)) or Cholestyramine (6 g three times a day) for a period of 10 months and after three months of wash-out (cross-over) the sequence was reversed for an additional 10 months. Blood pressure, lipid parameters, glycated haemoglobin and urinary albumin excretion were measured during the study. Additionally, in eight patients, urinary glycosaminoglycan excretion (GAG) was also measured during the study. Results Simvastatin and Cholestyramine were equally effective in reducing total and LDL cholesterol. Only during Simvastatin treatment a significant reduction in diastolic blood pressure and both 24 h urinary albumin and GAG excretion rates were observed, while no significant changes were seen with Cholestyramine treatment. Conclusions Our results clearly show for the first time that the reduction of blood pressure, together with 24 h urinary albumin excretion rate - two established cardiovascular risk factors, obtained during Simvastatin therapy in hypertensive type 2 diabetic patients - is in large part independent from the reduction of LDL Cholesterol.
引用
收藏
页码:980 / 987
页数:8
相关论文
共 49 条
  • [31] URINARY-EXCRETION OF ACIDIC GLYCOSAMINOGLYCANS IN AGED
    OHKAWA, S
    HATA, R
    NAGAI, Y
    SUGIURA, M
    [J]. JOURNAL OF BIOCHEMISTRY, 1972, 72 (06) : 1495 - 1501
  • [32] PEDERSEN TR, 1994, LANCET, V344, P1383
  • [33] PARTIAL REMISSION OF NEPHROTIC SYNDROME IN PATIENT ON LONG-TERM SIMVASTATIN
    RABELINK, AJ
    HENE, RJ
    ERKELENS, DW
    JOLES, JA
    KOOMANS, HA
    [J]. LANCET, 1990, 335 (8696) : 1045 - 1046
  • [34] Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia
    Ravid, M
    Brosh, D
    Ravid-Safran, S
    Levy, Z
    Rachmani, R
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (09) : 998 - 1004
  • [35] ALTERATIONS IN THE BASEMENT-MEMBRANE (HEPARAN-SULFATE) PROTEOGLYCAN IN DIABETIC MICE
    ROHRBACH, DH
    HASSELL, JR
    KLEINMAN, HK
    MARTIN, GR
    [J]. DIABETES, 1982, 31 (02) : 185 - 188
  • [36] PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
    SHEPHERD, J
    COBBE, SM
    FORD, I
    ISLES, CG
    LORIMER, AR
    MACFARLANE, PW
    MCKILLOP, JH
    PACKARD, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) : 1301 - 1307
  • [37] STUDIES ON MACROMOLECULAR COMPONENTS OF HUMAN GLOMERULAR-BASEMENT-MEMBRANE AND ALTERATIONS IN DIABETES - DECREASED LEVELS OF HEPARAN-SULFATE PROTEOGLYCAN AND LAMININ
    SHIMOMURA, H
    SPIRO, RG
    [J]. DIABETES, 1987, 36 (03) : 374 - 381
  • [38] CHARACTERIZATION OF GLYCOSAMINOGLYCANS IN URINE FROM PATIENTS WITH NEPHROTIC SYNDROME AND CONTROL SUBJECTS, AND THEIR EFFECTS ON LIPOPROTEIN-LIPASE
    STAPRANS, I
    GARON, SJ
    HOPPER, J
    FELTS, JM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1981, 678 (03) : 414 - 422
  • [39] URINARY ALBUMIN EXCRETION, CARDIOVASCULAR-DISEASE, AND ENDOTHELIAL DYSFUNCTION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    STEHOUWER, CDA
    NAUTA, JJP
    ZELDENRUST, GC
    HACKENG, WHL
    DONKER, AJM
    DENOTTOLANDER, GJH
    [J]. LANCET, 1992, 340 (8815) : 319 - 323
  • [40] EFFECTS OF PRAVASTATIN ON CARDIOVASCULAR REACTIVITY TO NOREPINEPHRINE AND ANGIOTENSIN-II PATIENTS WITH HYPERCHOLESTEROLEMIA AND SYSTEMIC HYPERTENSION
    STRAZNICKY, NE
    HOWES, LG
    LAM, W
    LOIS, WJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (08) : 582 - 586